Model List of Essential Medicines

Anti-D immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IV: 250 µg in single-dose vial ◦ Parenteral > General injections > IM: 250 µg in single-dose vial	Maternal care for red cell antibodies

Carbetocin

Section	Indications
Uterotonics ◦ Parenteral > General injections > IV: 100 µg per mL (heat stable)	Postpartum haemorrhage

Carboplatin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL	Other specified carcinomas of ovary

Cisplatin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL	Malignant neoplasms of cervix uteri

Clomifene

Section	Indications
Ovulation inducers ◦ Oral > Solid: 50 mg (citrate)	Female infertility without specification whether primary or secondary

Copper-containing intrauterine device

Section	Indications
Intrauterine devices ◦ -	Contact with health services for insertion of contraceptive device

Dexamethasone

Section	Indications
Other medicines administered to the mother ◦ Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))	Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

Ergometrine

Section	Indications
Uterotonics ◦ Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)	Postpartum haemorrhage

Estradiol cypionate + medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives ◦ Parenteral > General injections > IM: 5 mg + 25 mg	Contact with health services for reasons associated with reproduction

Ethinylestradiol + etonogestrel

Section	Indications
Intravaginal contraceptives ◦ Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg	Contact with health services for contraceptive management

Ethinylestradiol + levonorgestrel

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 50 µg + 250 µg [4] ◦ Oral > Solid: 30 µg + 150 µg	Contact with health services for postcoital contraception Contact with health services for contraceptive management

Ethinylestradiol + norethisterone

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 35 µg + 1 mg	Contact with health services for contraceptive management

Etonogestrel-releasing implant

Section	Indications
Implantable contraceptives ◦ Implant > Subdermal: 68 mg single rod	Contact with health services for insertion of contraceptive device

Folic acid

Section	Indications
Antianaemia medicines ◦ Oral > Solid: 400 µg	Cephalocele Anencephaly or similar anomalies Spina bifida

Levonorgestrel

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 750 µg [2]; 1.5 mg [1] ◦ Oral > Solid: 30 µg	Contact with health services for postcoital contraception Contact with health services for contraceptive management
Intrauterine devices ◦ Intrauterine system with reservoir containing 52 mg of levonorgestrel.	Contact with health services for insertion of contraceptive device

Levonorgestrel-releasing implant

Section	Indications
Implantable contraceptives ◦ Implant > Subdermal: 75 mg per rod (two-rods)	Contact with health services for insertion of contraceptive device

Medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives ◦ Parenteral > General injections > IM: 150 mg per mL in 1 mL vial ◦ Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system	Contact with health services for reasons associated with reproduction
Progestogens ◦ Oral > Solid: 5 mg	Excessive menstruation with irregular cycle

Methyldopa

Section	Indications
Antihypertensive medicines ◦ Oral > Solid: 250 mg	Gestational hypertension

Methylergometrine

Section	Indications
Uterotonics	Therapeutic equivalent to ergometrine for Postpartum haemorrhage

Mifepristone - misoprostol

Section	Indications
Medicines for medical abortion ◦ Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package	Unspecified time of fetal death, cause not specified Induced abortion

Misoprostol

Section	Indications
Uterotonics ◦ Local > Vaginal > tablet: 25 µg ◦ Oral > Solid: 200 µg	Unspecified obstetric condition Postpartum haemorrhage
Medicines for medical abortion ◦ Oral > Solid > tablet: 200 µg	Spontaneous abortion, incomplete, without complication

Multiple micronutrient supplement

Section	Indications
Other medicines administered to the mother ◦ Tablet containing: ◦ Vit A: 800 mcg retinol activity equivalent ◦ Vit C: 70 mg ◦ Vit D: 5 mcg (200 IU) ◦ Vit E: 10 mg alpha tocopherol equivalent ◦ Vit B1: 1.4 mg ◦ Vit B2: 1.4 mg ◦ Vit B3: 18 mg niacin equivalent ◦ Vit B6: 1.9 mg ◦ Folic acid: 400 mcg ◦ Vit B12: 2.6 mcg ◦ Iron: 30 mg ◦ Iodine: 150 mcg ◦ Zinc: 15 mg ◦ Selenium: 65 mcg ◦ Copper: 2 mg	Maternal care for other specified conditions predominantly related to pregnancy

Nifedipine

Section	Indications
Antioxytocics (tocolytics) ◦ Oral > Solid: 10 mg (immediate-release)	Preterm labour without delivery

Norethisterone

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 350 µg	Contact with health services for contraceptive management
Progestogens	Therapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle

Norethisterone enantate

Section	Indications
Injectable hormonal contraceptives ◦ Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution	Contact with health services for reasons associated with reproduction

Oxytocin

Section	Indications
Uterotonics ◦ Parenteral > General injections > unspecified: 10 IU per mL	Postpartum haemorrhage

Progesterone vaginal ring

Section	Indications
Intravaginal contraceptives ◦ Local > Vaginal > vaginal ring: 2.074 g micronized progesterone	Contact with health services for contraceptive management

Simvastatin

Section	Indications
Medicines for endocrine disorders ◦ Oral > Solid: 20 mg	Polycystic ovary syndrome

Sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > Medicines for chemoprevention ◦ Oral > Solid: 500 mg + 25 mg tablet	Malaria due to Plasmodium falciparum

Tranexamic acid

Section	Indications
Other medicines administered to the mother ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Postpartum haemorrhage

Ulipristal

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 30 mg tablet (ulipristal acetate)	Contact with health services for postcoital contraception